Regentis Biomaterials (RGNT): Director received 25K units
Keith Valentine, Director at Regentis Biomaterials, reported a grant / award of 25K units.
- 25K
- Derivative units
- Traded
- Jul 9, 2026
- Filed
- Jul 13, 2026
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Regentis Biomaterials
OQRO holds no insider, Congress, fund or contract record for Regentis Biomaterials dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RGNT page.
Other recent filings by Keith Valentine, Director
The full history of Keith Valentine, Director is on the profile page.
How this filing works
Explore the data
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data